Trastuzumab Based Therapy in HER2 Positive AGC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

98 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Trastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric cancer (AGC). However, the efficacy of routine trastuzumab therapy and its association with clinicopathologic factors remain unclear. The object of the study is to determine whether the addition of trastuzumab to first-line chemotherapy improves efficacy compared with chemotherapy alone in HER2 positive AGC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

NCT02004769

Stomach Neoplasms Neoplasms Metastasis ERBB2 Gene Amplification

COMPLETED PHASE2

Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

NCT04168931

Gastric Cancer Stage IV

TERMINATED PHASE2

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

NCT01260194

Gastric Cancer

TERMINATED PHASE4

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

NCT05975749

Gastric Cancer

RECRUITING PHASE2

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

NCT06846996

HER2-positive Gastric Cancer HER2-positive Gastroesophageal Junction

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 98 patients with HER2 positive AGC were enrolled in this prospective observational study. All patients were treated with trastuzumab plus chemotherapy as the first line therapy. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HER2 positive AGC treated with H+CT

HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.

H+CT

Intervention Type DRUG

All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H+CT

All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

trastuzumab plus chemotherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. pathology and medical imageology proven advanced gastric adenocarcinoma, inoperable;
2. received trastuzumab plus chemotherapy as the first-line palliative chemotherapy;
3. with measurable lesion with a diameter 20 mm using conventional computed tomography (CT) or magnetic resonance imaging (MRI) scans or 10 mm using spiral CT scans;
4. Eastern Cooperative Oncology Group performance status (ECOG PS ) of 0-2;
5. left ventricular ejection fraction(LVEF) more than 50 percents;
6. sufficient bone marrow, liver and renal function.

Exclusion Criteria

1. received previous systemic therapy for advanced disease (except adjuvant/neoadjuvant chemotherapy completed at least 6 months before enrollment);
2. trastuzumab based adjuvant/neoadjuvant therapy;
3. treatment with any other anticancer therapy (lapatinib, immunotherapy, etc);
4. patients with heart failure, coronary artery disease or myocardial infarction within the previous 6 months.
5. trastuzumab based first line therapy started beyond 4 weeks from the first diagnoses of AGC.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No